NCT04864652已完成不适用
Safety and Dosing Study of the CHILLS Cryotherapy for the Treatment of Obstructive Sleep Apnea (OSA): ARCTIC-1
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- Cryosa, Inc.
- 入组人数
- 84
- 试验地点
- 2
- 主要终点
- Incidence of Serious Procedure-Related Complications
研究概览
简要总结
ARCTIC-1 is a safety and dosing study to evaluate procedure tolerability in patients with clinically diagnosed moderate or severe OSA.
详细描述
The study is a safety and dose titration study to determine the optimum dose of Cryosa CHILLS cryotherapy in patients with clinically diagnosed moderate or severe OSA.
Up to 70 subjects are planned to be enrolled and treated with the device at up to 3 clinical sites in Latin America. Subjects will be followed for 90 days with evaluation intervals at discharge, 7 days, 30 days and 90 days post-procedure. Subjects agreeing to long-term follow-up will complete visits every 6 months through 2 years post-procedure.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 22 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age 25 - 65 years.
- •Diagnosed with moderate to severe OSA based on history and physical or have an established diagnosis of OSA (AHI ≥ 15 and ≤ 50) based on a prior sleep study.
- •BMI is between 28 kg/m2 and 40 kg/m2 at enrollment.
- •Negative result for COVID-19 polymerase chain reaction (RT-PCR) test and absence of clinical symptoms for COVID-19.
排除标准
- •Subjects with a high percentage of central apneas suggesting heart failure.
- •Contraindication to general anesthesia and MRI.
- •Metal braces, plate or pieces in the head or jaw that may interfere with MRI.
- •Craniofacial abnormality (e.g. retrognathia, micrognathia, etc.) thought to be the primary cause of OSA.
- •Obvious fixed upper airway obstructions (tumors, polyps, nasal obstruction) .
- •Tonsil size ≥ +
- •Previous surgery within 12 weeks of scheduled procedure performed on the soft tissue of the upper airway (e.g., uvula, soft palate or tonsils).
- •Oral cancer or non-healing oral wounds.
- •Presence of symptoms of influenza-like symptoms.
- •Contra-indicated for anesthesia or surgery.
- •History of surgery affecting the tongue (TORS, semi-glossectomy, RFBOT, MMA, HGNS).
- •History of radiation therapy to neck or upper respiratory tract
- •Surgical resection for cancer or congenital malformations in the larynx, tongue, or throat (with exception of tonsillectomy and/or adenoidectomy).
- •Clinical evidence of severe chronic obstructive or restrictive pulmonary disease (for example chronic bronchitis, emphysema, pulmonary fibrosis).
- •Active, severe pulmonary vascular disease (for example pulmonary arterial hypertension or pulmonary embolism).
- •Currently receiving treatment for severe cardiac valvular dysfunction, NYHA Class III or IV heart failure, unstable angina or recent (< 12 month) myocardial infarction or severe cardiac arrhythmias.
- •Subjects with bleeding event, known bleeding diathesis, impaired immunity for any reason, or heart attack or stroke within the last 12 months.
- •Clinical evidence of severe renal failure (Stage 4 or 5) undergoing dialysis or expected to institute dialysis within 12 months.
- •History or current clinical evidence of TIA or stroke or muscular dysfunction.
- •Taking medications that in the opinion of the consulting physician may alter consciousness, the pattern of respiration, or sleep architecture, such examples being benzodiazepines, opiates, neuroleptics, prescription stimulants, phenothiazine, or any form of chemical substance abuse.
- •History of dementia or active psychiatric disease that may impact study compliance.
- •Females who are pregnant or females of childbearing age with intention to become pregnant during the study period (≤ 3 months from treatment date).
- •Unable and/or unwilling to comply with study requirements or to provide written informed consent.
结局指标
主要结局
Incidence of Serious Procedure-Related Complications
时间窗: 30 Days
No serious procedure-related complications including death, loss of the airway requiring post-anesthesia care unit (PACU) re-intubation, persistent loss (more than 30 days) of tongue movement, or bleeding requiring surgical intervention or transfusion.
次要结局
未报告次要终点
研究者
研究点 (2)
Loading locations...
相似试验
招募中
1 期
The Safety and Efficacy of SNC-109 CAR-T Cells Therapy the Recurrent GlioblastomaRecurrent Glioblastoma MultiformeNCT05868083Shanghai Simnova Biotechnology Co.,Ltd.16
招募中
1 期
Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid TumorsPancreas CancerGastric CancerColon CancerEsophagus CancerLung CancerBreast CancerCholangiocarcinomaNCT06010862Chongqing Precision Biotech Co., Ltd36
进行中（未招募）
1 期
A Study of RC98 in Subjects With Advanced Malignant Solid TumorsSolid TumorsNCT04190823RemeGen Co., Ltd.63
已完成
1 期
Study to Assess PK, Safety and Tolerability in Healthy SubjectsAcute Ischemic StrokeNCT06380699Changzhou Qianhong Bio-pharma Co., Ltd.56
已完成
不适用
Evaluation of Tolerability and Safety of "Allergovac Poliplus" in Polysensitized Patients With Rhinitis or Allergic Rhinoconjunctivitis With or Without Asthma: A Study in Daily Clinical PracticeAsthmaRhinoconjunctivitisAllergic RhinitisNCT02844842Roxall Medicina España S.A152